Last edition
News about "Wockhardt Bio AG"
Wockhardt Realigns US Operations to Focus on Innovative Portfolio, Exits Generic Pharma Segment
Wockhardt has announced a strategic realignment of its US operations, exiting the loss-making generics business to focus on its innovation-led priorities in novel antibiotics and biologics, marking a decisive shift toward building a differentiated, future-ready pharmaceutical enterprise.
Wockhardt Bio AG | 11/07/2025 | By Mrinmoy Dey | 134
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members